gsk1120212
Rare Cancers
Novartis PharmaceuticalsPhase 4 / ApprovedActive
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Rare Cancers cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Dabrafenib Novartis Pharmaceuticals | Phase 4 | B |
Same molecule, other indications
gsk1120212 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →